Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years

Figure 1 Dynamics of mean alanine aminotransferase and aspartate aminotransferase reduction after tenofovir disoproxil fumarate switching to tenofovir alafenamide. The dynamic changes of mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (U/L) including standard deviations are shown on the Y-axis. The time course of switching is shown on the X-axis. There was persistent improvement of mean ALT and AST reduction after switching from tenofovir disoproxil fumarate to tenofovir alafenamide up to week 144 (P < 0. 001). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.

Figure 2 Improvement rates (%) of alanine aminotransferase and aspartate aminotransferase to < 35 (male)/25 (female) and < 30 (male)/19 (female), aspartate aminotransferase to platelet ratio index to < 0. 5 and fibrosis-4 to < 1.45 at baseline and after switching week 144. A and B: There was a great improvement rates of alanine aminotransferase and aspartate aminotransferase to normalization (A) and improvement rates of aspartate aminotransferase to platelet ratio index to < 0.5 and fibrosis-4 to < 1.45 (B) after tenofovir disoproxil fumarate switching to tenofovir alafenamide for 144 weeks, compared to baseline. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; FIB-4: Fibrosis-4; APRI: Aspartate aminotransferase to platelet ratio index.

Figure 3 Changes in mean scores of aspartate aminotransferase to platelet ratio index, fibrosis-4, and shear wave elastography reading after tenofovir disoproxil fumarate switching to tenofovir alafenamide, compared to baseline. A-C: The changes in mean score of aspartate aminotransferase to platelet ratio index (APRI) (A), fibrosis-4 (FIB-4) (B), and shear wave elastography (SWE) reading (C) with standard deviations are shown on the y-axis. The time course of switching is shown on the x-axis. There was a great reduction in the mean scores for both APRI (A), FIB-4 (B) scores at switching week 144 and SWE reading (C) at a mean of 109 weeks switching from tenofovir disoproxil fumarate to tenofovir alafenamide (P < 0.001). FIB-4: Fibrosis-4; APRI: Aspartate aminotransferase to platelet ratio index; SWE: Shear wave elastography.